search
Back to results

Safety and Efficacy of Endovascular Repair of Complex Aortic Pathology With Physician-modified Endovascular Grafts (PMEGs)

Primary Purpose

Abdominal Aortic Aneurysm, Thoracoabdominal Aortic Aneurysm, Aortic Dissection

Status
Recruiting
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
Endovascular aortic repair with a physician-modified endovascular graft (PMEG)
Sponsored by
Beth Israel Deaconess Medical Center
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Abdominal Aortic Aneurysm focused on measuring Fenestrated endovascular aortic repair, Branched endovascular aortic repair, Complex aortic aneurysm repair

Eligibility Criteria

21 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

INCLUSION CRITERIA:

General inclusion criteria (applicable to all 3 study arms):

  • Aortic pathology that fits one of the study arms (see below for detailed description)
  • Aortic pathology that cannot be treated within the Instructions for Use of an FDA- approved, commercially-available device
  • Aortic aneurysm that can be treated within the Instructions for Use of an FDA-approved, commercially-available custom-manufactured device but deemed unsafe to wait the required time for device manufacturing
  • Subject is at high-risk of morbidity and mortality with open surgical repair based on cardiopulmonary function, extent of comorbid disease, and anatomic complexity
  • Iliac and/or femoral access vessel morphology that is compatible with vascular access techniques, devices, or accessories, with or without use of a surgical or endovascular conduit
  • Non-aneurysmal aortic segment proximal to the aortic pathology with a:

    • Minimum neck length of 20 mm
    • Diameter between 20 - 42 mm
  • Non-aneurysmal aortic or iliac segment distal to the aortic pathology with:

    • Aortic distal fixation site greater than 20 mm in length and diameter between 20-42 mm
    • Iliac artery distal fixation site greater than 10 mm in length and diameter range 8- 25 mm
  • Age ≥21 years old
  • Life expectancy: ≥2 years

Arm1:

  • Complex abdominal aortic aneurysm, specifically juxtarenal or suprarenal abdominal aortic aneurysm or type IV thoracoabdominal aortic aneurysm, with maximum diameter of ≥5.5 cm for men or ≥5.0 cm for women, growth ≥0.5 cm in 6 months, or concomitant iliac aneurysm ≥3 cm
  • Prior endovascular aortic aneurysm repair with loss of proximal seal requiring incorporation of the renal arteries, SMA, and/or CA for repair, without aneurysmal disease extending above the diaphragmatic hiatus
  • Prior open abdominal aortic aneurysm repair with aneurysmal disease proximal to the repair requiring incorporation of the renal arteries, SMA, and/or CA for repair, without aneurysmal disease above the diaphragmatic hiatus
  • Saccular complex abdominal aortic aneurysm deemed at significant risk for rupture
  • Symptomatic complex aortic aneurysm
  • Penetrating aortic ulcer with depth ≥1 cm or width ≥2 cm, for which endovascular repair requires incorporation of the renal arteries, SMA, and/or CA, without involvement of the aorta above the diaphragmatic hiatus
  • Aortic pseudoaneurysm for which endovascular repair requires incorporation of the renal arteries, SMA, and/or CA, without involvement of the aorta above the diaphragmatic hiatus

Arm2:

  • Type I, II, or III thoracoabdominal aortic aneurysm with maximum diameter of ≥5.5 cm, or growth ≥0.5 cm in 6 months
  • Prior endovascular aortic aneurysm repair with loss of proximal seal requiring incorporation of the renal arteries, SMA, and/or CA for repair with aneurysmal disease extending above the diaphragmatic hiatus
  • Prior thoracic endovascular aneurysm repair with loss of distal seal requiring incorporation of the renal arteries, SMA, and/or CA for repair
  • Prior open abdominal aortic aneurysm repair with aneurysmal disease proximal to the repair requiring incorporation of the renal arteries, SMA, and/or CA for repair, with aneurysmal disease above the diaphragmatic hiatus
  • Saccular type I, II, or III thoracoabdominal aortic aneurysm deemed at significant risk for rupture
  • Symptomatic type I, II, or III thoracoabdominal aortic aneurysm
  • Penetrating aortic ulcer with depth ≥1 cm or width ≥2 cm, for which endovascular repair requires incorporation of the renal arteries, SMA, and/or CA, with involvement of the aorta above the diaphragmatic hiatus
  • Aortic pseudoaneurysm for which endovascular repair requires incorporation of the renal arteries, SMA, and/or CA, with involvement of the aorta above the diaphragmatic hiatus

Arm 3:

  • Acute or chronic type B aortic dissection with indication for repair including, but not limited to renal, mesenteric, or lower extremity malperfusion, progression of dissection, or persistence of symptoms despite optimal medical therapy
  • Prior repair of type A dissection and development of acute or chronic type B dissection component with indication for repair (listed above)
  • Aortic intramural hematoma (IMH) with indication for repair including, but not limited to renal, mesenteric, or lower extremity malperfusion, progression of dissection, or more typically, persistence of symptoms despite optimal medical therapy

EXCLUSION CRITERIA:

General Exclusion Criteria

  • Subject is eligible for enrollment in a manufacturer-sponsored IDE at the investigational site
  • Subject is unwilling to comply with the follow-up schedule
  • Inability or refusal to give informed consent by subject or legal representative
  • Subject is pregnant or breastfeeding
  • Subject has a ruptured aneurysm

Medical Exclusion Criteria

  • Known sensitivities or allergies to the materials of construction of the devices
  • Known hypersensitivity or contraindication to anticoagulation or contrast media that cannot be adequately medically managed
  • Uncorrectable coagulopathy
  • Body habitus that would inhibit x-ray visualization of the aorta or exceeds the safe capacity of the equipment
  • Systemic or local infection that may increase the risk of endovascular graft infection
  • Diagnosis of connective tissue disorders (e.g., Marfan Syndrome, Ehler's Danlos Syndrome)

Anatomic Exclusion Criteria

  • Inability to perform open or endovascular iliac conduit in patients with inadequate femoral/iliac access
  • Excessive thrombus or calcification within the neck of the aneurysm
  • Visceral vessel anatomy not compatible with placement of a physician-modified endovascular graft due to occlusive disease or small size

Sites / Locations

  • Beth Israel Deaconess Medical CenterRecruiting

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm Type

Experimental

Experimental

Experimental

Arm Label

Complex abdominal aortic aneurysm (AAA)

Thoracoabdominal aortic aneurysm (TAAA)

Type B aortic dissection

Arm Description

Includes juxtarenal AAA, suprarenal AAA, and type IV thoracoabdominal aortic aneurysm

Includes Type I, Type II, and Type III TAAA

Outcomes

Primary Outcome Measures

Perioperative mortality
Rate of death
Perioperative major adverse events
Rates of: Stroke Respiratory failure (defined as postoperative intubation >48 hours or reintubation) Myocardial infarction Bowel ischemia requiring treatment Renal failure requiring dialysis Acute limb ischemia Paraplegia
All-cause mortality
Rate of death due to any cause at: 30-days, 6-months, 1-year, and annually to 5-years
Aneurysm-related mortality
Rate of aneurysm-related death at: 30-days, 6-months, 1-year, and annually to 5-years
Long-term major adverse events
Rate of major adverse events at: 6-months, 1-year, and annually to 5-years Long-term major adverse event is defined as having at least one of the following: Death Stroke (deemed related to the device, the procedure, or a reintervention) Bowel ischemia requiring treatment (deemed related to the device, the procedure, or a reintervention) Renal failure requiring dialysis (deemed related to the device, the procedure, reintervention, or follow-up imaging) Acute limb ischemia (deemed related to the device, the procedure, or a reintervention)
Technical success
Defined as successful delivery of the physician-modified graft in the planned location with patency of all intended target vessels and without unintentional coverage of any aortic branches, along with successful removal of the delivery system
Device-related reintervention
Rate of device-related reintervention at: 30-days, 6-months, 1-year, and annually to 5-years
Aneurysm rupture
Rate of aneurysm rupture at: 30-days, 6-months, 1-year, and annually to 5-years
Conversion to open repair
Rate of conversion to open repair at: 30-days, 6-months, 1-year, and annually to 5-years
Endoleaks
Rate of Type I, II, III, IV, and V endoleaks at: 30-days, 6-months, 1-year, and annually to 5-years
Main device occlusion
Rate of main device occlusion at: 30-days, 6-months, 1-year, and annually to 5-years
Target vessel patency
Rate of target vessel patency at: 30-days, 6-months, 1-year, and annually to 5-years
Residual aneurysm sac status
Rate of residual sac status (stable, regressing, expanding) at 6-months, 1-year, and annually to 5-years, defined as the following: Stable: maximum diameter within 5 mm of the diameter at 30-day follow-up Regressing: maximum diameter ≥5 mm less than the diameter at 30-day follow-up Expanding: maximum diameter ≥5 mm greater than the diameter at 30-day follow-up

Secondary Outcome Measures

Full Information

First Posted
January 28, 2021
Last Updated
August 22, 2023
Sponsor
Beth Israel Deaconess Medical Center
search

1. Study Identification

Unique Protocol Identification Number
NCT04746677
Brief Title
Safety and Efficacy of Endovascular Repair of Complex Aortic Pathology With Physician-modified Endovascular Grafts (PMEGs)
Official Title
Single-Center Investigational Device Exemption Trial: Safety and Efficacy of Endovascular Repair of Complex Aortic Pathology With Physician-modified Endovascular Grafts (PMEGs)
Study Type
Interventional

2. Study Status

Record Verification Date
August 2023
Overall Recruitment Status
Recruiting
Study Start Date
March 15, 2021 (Actual)
Primary Completion Date
December 31, 2023 (Anticipated)
Study Completion Date
December 31, 2028 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Beth Israel Deaconess Medical Center

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
Yes
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
The primary objective of this study is to examine the safety and effectiveness of physician-modified endovascular grafts (PMEGs) for endovascular repair of complex aortic pathology in high-risk patients. The study is divided into three study arms based on the subject's aortic pathology: (1) Complex abdominal aortic aneurysm (AAA); (2) Thoracoabdominal aortic aneurysm; and (3) Aortic dissection.
Detailed Description
Complex aortic pathology, comprised of aneurysmal disease and aortic dissection involving the visceral aortic segment, presents a technical challenge for repair due to involvement of the renal and/or mesenteric arteries. Traditionally, the gold standard for repair has been open repair. However, open repair of these diseases is associated with high perioperative morbidity and mortality. Therefore, for patients with significant medical comorbidities or complex surgical/anatomical features, the risk of open surgery may be prohibitive. As endovascular techniques have become increasingly advanced, options for the endovascular treatment of complex aortic pathology involving the visceral segment have been developed. The predominant approach is fenestrated or branched endovascular aortic repair (F/B-EVAR) with fenestrated or branched endovascular grafts. Currently, there is only one device FDA-approved for commercial use in the United States, the Zenith Fenestrated AAA Endovascular Graft (Cook Medical, Bloomington, IN). However, its use is limited by the design specifications of the device and the required manufacturing time in patients requiring more urgent repair. Therefore, many patients with complex aortic pathology are not eligible for repair with this device, and there are currently no other FDA-approved options for definitive repair. One option for definitive repair of complex aortic pathology in patients ineligible for the Zenith fenestrated device is endovascular repair with a physician-modified endovascular graft (PMEG). For this procedure, the operating surgeon modifies an FDA-approved endovascular graft to incorporate fenestrations or branches based on the patient's anatomy. Numerous reports have been published demonstrating that this procedure can be performed with high technical success, and acceptable perioperative and mid-term results in high-risk patients. The primary objective of the study is to evaluate safety and effectiveness of PMEGs for the endovascular repair of complex aortic pathology in high-risk patients. The safety outcomes include perioperative mortality (defined as death <30 days postoperative or during the index hospitalization) and major adverse events, along with mortality and adverse events during follow-up. Effectiveness outcomes include initial technical success, endoleak rate, target vessel patency, and rate of reintervention. Patients will be followed for five years. Patients will be evaluated preoperatively, at the time of the procedure, at the time of discharge from the index hospitalization, 1-month post-procedure, 6-months post-procedure, and 1-year post-procedure, and annually for five-years.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Abdominal Aortic Aneurysm, Thoracoabdominal Aortic Aneurysm, Aortic Dissection
Keywords
Fenestrated endovascular aortic repair, Branched endovascular aortic repair, Complex aortic aneurysm repair

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Non-Randomized
Enrollment
45 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Complex abdominal aortic aneurysm (AAA)
Arm Type
Experimental
Arm Description
Includes juxtarenal AAA, suprarenal AAA, and type IV thoracoabdominal aortic aneurysm
Arm Title
Thoracoabdominal aortic aneurysm (TAAA)
Arm Type
Experimental
Arm Description
Includes Type I, Type II, and Type III TAAA
Arm Title
Type B aortic dissection
Arm Type
Experimental
Intervention Type
Device
Intervention Name(s)
Endovascular aortic repair with a physician-modified endovascular graft (PMEG)
Intervention Description
Endovascular aortic repair with a physician-modified endovascular graft (PMEG)
Primary Outcome Measure Information:
Title
Perioperative mortality
Description
Rate of death
Time Frame
Up to 30-days after surgery
Title
Perioperative major adverse events
Description
Rates of: Stroke Respiratory failure (defined as postoperative intubation >48 hours or reintubation) Myocardial infarction Bowel ischemia requiring treatment Renal failure requiring dialysis Acute limb ischemia Paraplegia
Time Frame
Up to 30-days after surgery
Title
All-cause mortality
Description
Rate of death due to any cause at: 30-days, 6-months, 1-year, and annually to 5-years
Time Frame
30-days to 5-years
Title
Aneurysm-related mortality
Description
Rate of aneurysm-related death at: 30-days, 6-months, 1-year, and annually to 5-years
Time Frame
30-days to 5-years
Title
Long-term major adverse events
Description
Rate of major adverse events at: 6-months, 1-year, and annually to 5-years Long-term major adverse event is defined as having at least one of the following: Death Stroke (deemed related to the device, the procedure, or a reintervention) Bowel ischemia requiring treatment (deemed related to the device, the procedure, or a reintervention) Renal failure requiring dialysis (deemed related to the device, the procedure, reintervention, or follow-up imaging) Acute limb ischemia (deemed related to the device, the procedure, or a reintervention)
Time Frame
6-months to 5-years
Title
Technical success
Description
Defined as successful delivery of the physician-modified graft in the planned location with patency of all intended target vessels and without unintentional coverage of any aortic branches, along with successful removal of the delivery system
Time Frame
24 hours
Title
Device-related reintervention
Description
Rate of device-related reintervention at: 30-days, 6-months, 1-year, and annually to 5-years
Time Frame
30-days to 5-years
Title
Aneurysm rupture
Description
Rate of aneurysm rupture at: 30-days, 6-months, 1-year, and annually to 5-years
Time Frame
30-days to 5-years
Title
Conversion to open repair
Description
Rate of conversion to open repair at: 30-days, 6-months, 1-year, and annually to 5-years
Time Frame
30-days to 5-years
Title
Endoleaks
Description
Rate of Type I, II, III, IV, and V endoleaks at: 30-days, 6-months, 1-year, and annually to 5-years
Time Frame
30-days to 5-years
Title
Main device occlusion
Description
Rate of main device occlusion at: 30-days, 6-months, 1-year, and annually to 5-years
Time Frame
30-days to 5-years
Title
Target vessel patency
Description
Rate of target vessel patency at: 30-days, 6-months, 1-year, and annually to 5-years
Time Frame
30-days to 5-years
Title
Residual aneurysm sac status
Description
Rate of residual sac status (stable, regressing, expanding) at 6-months, 1-year, and annually to 5-years, defined as the following: Stable: maximum diameter within 5 mm of the diameter at 30-day follow-up Regressing: maximum diameter ≥5 mm less than the diameter at 30-day follow-up Expanding: maximum diameter ≥5 mm greater than the diameter at 30-day follow-up
Time Frame
6-months, 1-year, and annually to 5-years

10. Eligibility

Sex
All
Minimum Age & Unit of Time
21 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
INCLUSION CRITERIA: General inclusion criteria (applicable to all 3 study arms): Aortic pathology that fits one of the study arms (see below for detailed description) Aortic pathology that cannot be treated within the Instructions for Use of an FDA- approved, commercially-available device Aortic aneurysm that can be treated within the Instructions for Use of an FDA-approved, commercially-available custom-manufactured device but deemed unsafe to wait the required time for device manufacturing Subject is at high-risk of morbidity and mortality with open surgical repair based on cardiopulmonary function, extent of comorbid disease, and anatomic complexity Iliac and/or femoral access vessel morphology that is compatible with vascular access techniques, devices, or accessories, with or without use of a surgical or endovascular conduit Non-aneurysmal aortic segment proximal to the aortic pathology with a: Minimum neck length of 20 mm Diameter between 20 - 42 mm Non-aneurysmal aortic or iliac segment distal to the aortic pathology with: Aortic distal fixation site greater than 20 mm in length and diameter between 20-42 mm Iliac artery distal fixation site greater than 10 mm in length and diameter range 8- 25 mm Age ≥21 years old Life expectancy: ≥2 years Arm1: Complex abdominal aortic aneurysm, specifically juxtarenal or suprarenal abdominal aortic aneurysm or type IV thoracoabdominal aortic aneurysm, with maximum diameter of ≥5.5 cm for men or ≥5.0 cm for women, growth ≥0.5 cm in 6 months, or concomitant iliac aneurysm ≥3 cm Prior endovascular aortic aneurysm repair with loss of proximal seal requiring incorporation of the renal arteries, SMA, and/or CA for repair, without aneurysmal disease extending above the diaphragmatic hiatus Prior open abdominal aortic aneurysm repair with aneurysmal disease proximal to the repair requiring incorporation of the renal arteries, SMA, and/or CA for repair, without aneurysmal disease above the diaphragmatic hiatus Saccular complex abdominal aortic aneurysm deemed at significant risk for rupture Symptomatic complex aortic aneurysm Penetrating aortic ulcer with depth ≥1 cm or width ≥2 cm, for which endovascular repair requires incorporation of the renal arteries, SMA, and/or CA, without involvement of the aorta above the diaphragmatic hiatus Aortic pseudoaneurysm for which endovascular repair requires incorporation of the renal arteries, SMA, and/or CA, without involvement of the aorta above the diaphragmatic hiatus Arm2: Type I, II, or III thoracoabdominal aortic aneurysm with maximum diameter of ≥5.5 cm, or growth ≥0.5 cm in 6 months Prior endovascular aortic aneurysm repair with loss of proximal seal requiring incorporation of the renal arteries, SMA, and/or CA for repair with aneurysmal disease extending above the diaphragmatic hiatus Prior thoracic endovascular aneurysm repair with loss of distal seal requiring incorporation of the renal arteries, SMA, and/or CA for repair Prior open abdominal aortic aneurysm repair with aneurysmal disease proximal to the repair requiring incorporation of the renal arteries, SMA, and/or CA for repair, with aneurysmal disease above the diaphragmatic hiatus Saccular type I, II, or III thoracoabdominal aortic aneurysm deemed at significant risk for rupture Symptomatic type I, II, or III thoracoabdominal aortic aneurysm Penetrating aortic ulcer with depth ≥1 cm or width ≥2 cm, for which endovascular repair requires incorporation of the renal arteries, SMA, and/or CA, with involvement of the aorta above the diaphragmatic hiatus Aortic pseudoaneurysm for which endovascular repair requires incorporation of the renal arteries, SMA, and/or CA, with involvement of the aorta above the diaphragmatic hiatus Arm 3: Acute or chronic type B aortic dissection with indication for repair including, but not limited to renal, mesenteric, or lower extremity malperfusion, progression of dissection, or persistence of symptoms despite optimal medical therapy Prior repair of type A dissection and development of acute or chronic type B dissection component with indication for repair (listed above) Aortic intramural hematoma (IMH) with indication for repair including, but not limited to renal, mesenteric, or lower extremity malperfusion, progression of dissection, or more typically, persistence of symptoms despite optimal medical therapy EXCLUSION CRITERIA: General Exclusion Criteria Subject is eligible for enrollment in a manufacturer-sponsored IDE at the investigational site Subject is unwilling to comply with the follow-up schedule Inability or refusal to give informed consent by subject or legal representative Subject is pregnant or breastfeeding Subject has a ruptured aneurysm Medical Exclusion Criteria Known sensitivities or allergies to the materials of construction of the devices Known hypersensitivity or contraindication to anticoagulation or contrast media that cannot be adequately medically managed Uncorrectable coagulopathy Body habitus that would inhibit x-ray visualization of the aorta or exceeds the safe capacity of the equipment Systemic or local infection that may increase the risk of endovascular graft infection Diagnosis of connective tissue disorders (e.g., Marfan Syndrome, Ehler's Danlos Syndrome) Anatomic Exclusion Criteria Inability to perform open or endovascular iliac conduit in patients with inadequate femoral/iliac access Excessive thrombus or calcification within the neck of the aneurysm Visceral vessel anatomy not compatible with placement of a physician-modified endovascular graft due to occlusive disease or small size
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Theresa Bishop, BSN
Phone
617-632-9975
Email
tbishop@bidmc.harvard.edu
First Name & Middle Initial & Last Name or Official Title & Degree
Mary Trovato
Phone
617-632-7488
Email
mtrovato@bidmc.harvard.edu
Facility Information:
Facility Name
Beth Israel Deaconess Medical Center
City
Boston
State/Province
Massachusetts
ZIP/Postal Code
02215
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Theresa Bishop
Phone
617-632-9975
Email
tbishop@bidmc.harvard.edu
First Name & Middle Initial & Last Name & Degree
Mary Trovato
Phone
617-632-7488
Email
mtrovato@bidmc.harvard.edu
First Name & Middle Initial & Last Name & Degree
Marc L Schermerhorn, MD
First Name & Middle Initial & Last Name & Degree
Nicholas J Swerdlow, MD

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

Safety and Efficacy of Endovascular Repair of Complex Aortic Pathology With Physician-modified Endovascular Grafts (PMEGs)

We'll reach out to this number within 24 hrs